Epizyme dis­cards a failed pro­gram for tazeme­to­stat as ex­ecs work to get an FDA hold lift­ed -- shares crater

Epizyme’s woes with its lead pro­gram for tazeme­to­stat just got much worse.

The FDA stepped in and slapped a par­tial hold on their $EPZM lead drug — halt­ing en­roll­ment in clin­i­cal tri­als — close to three months ago af­ter a pe­di­atric pa­tient de­vel­oped a sec­ondary T-cell lym­phoblas­tic lym­phoma. To­day in its Q2 re­port Epizyme added that it is shut­ting down a top-ranked de­vel­op­ment pro­gram for dif­fuse large B-cell lym­phoma, DL­B­CL, af­ter con­clud­ing that it wouldn’t suc­ceed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER